SCHEMBL6468174

SCHEMBL6468174

[CH2]CCCCOc1ccc(OCC)cc1

nearest known ligand 0.61

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NQO1 P15559 1/20 0.61
KDM4E B2RXH2 4/20 0.60
ALDH1A1 P00352 4/20 0.60
SMN1; SMN2 Q16637 1/20 0.57
TSHR P16473 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
LMNA P02545 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
MAPT P10636 1/20 0.47
NR5A1 Q13285 1/20 0.47
LTA4H P09960 4/20 0.47
POLB P06746 1/20 0.46
KCNA3 P22001 1/20 0.44
NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9243166 0.93 NQO1 (0.64) NQO1KDM4EALDH1A1SMN1; SMN2TSHR
SCHEMBL7477094 0.87 NR5A1 (0.62) TSHRLMNAMAPTNR5A1LTA4H
SCHEMBL8458055 0.87 NR5A1 (0.62) TSHRLMNAMAPTNR5A1LTA4H
SCHEMBL11042247 0.86 NQO1 (0.67) NQO1KDM4EALDH1A1SMN1; SMN2TSHR
SCHEMBL14984021 0.86 NQO1 (0.74) NQO1KDM4EALDH1A1SMN1; SMN2TSHR
SCHEMBL7324144 0.85 NR5A1 (0.66) TSHRLMNAMAPTNR5A1LTA4H
SCHEMBL1044318 0.83 DRD2 (0.57) KDM4EALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL1044851 0.83 MAPT (0.53) ALDH1A1SMN1; SMN2TDP1LMNAL3MBTL1
SCHEMBL8778513 0.82 LTA4H (0.57) SMN1; SMN2TSHRLMNAMAPTNR5A1
1-Butyloxy-4-Ethoxybenzene SCHEMBL27940791 0.82 NQO1 (0.67) NQO1KDM4EALDH1A1SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050107468-A1 Process for the preparation of an enantiomerically enriched thio compound DSM IP ASSETS B.V. (NL) 2005-05-19 US disclosed
EP-1453797-A1 PROCESS FOR THE PREPARATION OF AN ENANTIOMERICALLY ENRICHED THIO COMPOUND DSM IP Assets B.V. (NL) 2004-09-08 EP disclosed
EP-1325908-A1 Process for the preparation of an enantiomerically enriched thio compound DSM N.V. (NL) 2003-07-09 EP disclosed
WO-2003051827-A1 PROCESS FOR THE PREPARATION OF AN ENANTIOMERICALLY ENRICHED THIO COMPOUND DSM IP ASSETS B.V. (NL) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107468-A1 Process for the preparation of an enantiomerically enriched thio compound SLC7A1, TCP1, TFRC NQO1 2165/4885KDM4E 2320/4885ALDH1A1 1036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.